Drugs in Context Psychiatry welcomes a broad range of article types including original research, study protocols and review articles.
In line with the principle of providing context for healthcare professionals (HCPs) to properly inform and improve disease management in real world medicine, we especially encourage the submission of articles that provide context for trials of drug interventions in order to motivate improvements in disease management by HCPs practising medicine in the front line.
Review
This articles aims is to provide useful information and insights for the management of opioid agonist therapy by providing an overview that ranges from the characteristics of opioid use disorder patients to the macroscopic phenomena of social-health significance on a national scale, with a particular focus on the Italian territory.
Review
In this review, the lurasidone development programme for adult and paediatric patients is described. In addition, the pharmacokinetic and pharmacodynamic characteristics of lurasidone are revisited, pivotal clinical studies conducted on both adults and children are summarized, and several clinical cases are also presented.
Review
There is some evidence that propranolol may benefit individuals with behavioural and psychological symptoms of dementia (BPSD). This article discusses three case series that assessed the use of propranolol for the management of BPSD. From these studies, it appears that propranolol improves BPSD and is well tolerated. In clinical practice, the routine use of propranolol among people with BPSD cannot be recommended at this time given the limited data. However, propranolol can be trialled among individuals with BPSD when symptoms have not responded adequately to other medications.
Case Report
This paper evaluates the efficacy and safety of cannabidiol isolate as a personalized treatment in patients with anxiety disorders through the presentation of four clinical cases.
Review
The goal of this report is to identify, from a systematic review of the literature, the evidence for using prazosin in the management of behavioural and psychological symptoms of dementia including agitation and aggression from controlled studies.
